Informationen:
Fehler:
ID
32694
Beschreibung
A Study for Type 2 Diabetic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00548808
Link
https://clinicaltrials.gov/show/NCT00548808
Stichworte
Versionen (1)
- 12.11.18 12.11.18 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
12. November 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Type 2 Diabetes Mellitus NCT00548808
Eligibility Type 2 Diabetes Mellitus NCT00548808
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Type 2 Diabetes Mellitus NCT00548808
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Hypoglycemic Agents Oral | Metformin | Insulin injection Absent
Item
receiving oral antihyperglycemic medications (including metformin) without insulin injection in the last 90 days
boolean
C0020616 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0025598 (UMLS CUI [2])
C0199782 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C1527415 (UMLS CUI [1,2])
C0025598 (UMLS CUI [2])
C0199782 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) equal to or greater than 7.0% but less than 11.0%
boolean
C0474680 (UMLS CUI [1])
Insulin injection Willing | Hypoglycemic Agents Oral Continuing
Item
willing to receive insulin injection while continuing to take the prestudy oral antihyperglycemic medications
boolean
C0199782 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
C0020616 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0549178 (UMLS CUI [2,3])
C0600109 (UMLS CUI [1,2])
C0020616 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0549178 (UMLS CUI [2,3])
Blood Glucose Self-Monitoring Perform Able
Item
able to perform self monitoring of blood glucose
boolean
C0005803 (UMLS CUI [1,1])
C0884358 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0884358 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
Hypoglycemic Agents | Exception Metformin | Exception Sulfonylureas | Exception Thiazolidinediones | Exception Pioglitazone
Item
are taking any other glucose-lowering agents other than metformin, sulfonylurea or thiazolidinedione (pioglitazone)
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0038766 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1257987 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0071097 (UMLS CUI [5,2])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0038766 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1257987 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0071097 (UMLS CUI [5,2])
Acarbose | miglitol | Pramlintide | exenatide | repaglinide | nateglinide
Item
have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks
boolean
C0050393 (UMLS CUI [1])
C0066535 (UMLS CUI [2])
C0537551 (UMLS CUI [3])
C0167117 (UMLS CUI [4])
C0246689 (UMLS CUI [5])
C0903898 (UMLS CUI [6])
C0066535 (UMLS CUI [2])
C0537551 (UMLS CUI [3])
C0167117 (UMLS CUI [4])
C0246689 (UMLS CUI [5])
C0903898 (UMLS CUI [6])
Body mass index
Item
have a body mass index greater than 35 kg/m2
boolean
C1305855 (UMLS CUI [1])
Kidney Disease
Item
history or presence of kidney disease
boolean
C0022658 (UMLS CUI [1])
Heart Disease New York Heart Association Classification
Item
have cardiac disease (class iii or iv)
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C1275491 (UMLS CUI [1,2])